Black Rock Inc. V Tv Therapeutics Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.42 - $0.75 $618 - $1,104	-1,473 Reduced 2.67%	53,661 $25,000
Q2 2023 Aug 11, 2023	BUY	$0.72 - $0.95 $31 - $41	44 Added 0.08%	55,134 $40,000
Q1 2023 May 12, 2023	SELL	$0.72 - $1.01 $104 - $146	-145 Reduced 0.26%	55,090 $44,000
Q4 2022 Feb 13, 2023	SELL	$0.66 - $40.8 $122 - $7,547	-185 Reduced 0.33%	55,235 $36,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $38.8 $186 - $11,135	-287 Reduced 0.52%	55,420 $54,000
Q2 2022 Aug 12, 2022	SELL	$0.39 - $0.84 $21,699 - $46,736	-55,639 Reduced 49.97%	55,707 $42,000
Q1 2022 May 12, 2022	SELL	$0.51 - $1.0 $1,340 - $2,628	-2,628 Reduced 2.31%	111,346 $80,000
Q4 2021 Feb 10, 2022	BUY	$0.95 - $1.69 $14,475 - $25,750	15,237 Added 15.43%	113,974 $113,000
Q3 2021 Nov 09, 2021	BUY	$1.53 - $2.22 $1,295 - $1,880	847 Added 0.87%	98,737 $150,000
Q2 2021 Aug 11, 2021	BUY	$2.27 - $3.44 $222,210 - $336,741	97,890 New	97,890 $224,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.1B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.